Tonix Pharma (TNXP) Says TNX-102 SL Phase 3 Did Not Meet Primary Endpoint in Fibromyalgia

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 5/26/2022

1. NVDA
2. SNOW
3. SPLK
4. NTNX
5. WSM

6. ENS
7. DXC
8. DKS
9. VMW
10. MDT

Top News Most Read Special Reports

S&P, Dow futures edge higher ahead of GDP data; Nvidia slides
Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
NVIDIA (NVDA) Falls on Downbeat Guidance, Evercore ISI Remains a Buyer as Shares Trade Near an 'Estimated Floor of $150'
Apple (AAPL) Stock Dips on Report It Expects Flat iPhone Production This Year
'His Personality Suggests Resolution Depends on Him Alone': Jefferies Discusses Elon Musk, Cuts PT on Tesla (TSLA) on Increased Risk Profile

Go back to Tonix Pharma (TNXP) Says TNX-102 SL Phase 3 Did Not Meet Primary Endpoint in Fibromyalgia

TONIX PHARM HLDG (NASDAQ: TNXP)						Delayed: 1.99 --0 (-0%)
Previous Close	$1.99		52 Week High	$7.95
Open	$1.99		52 Week Low	$0.40
Day High	$1.99		P/E	N/A
Day Low	$1.99		EPS	$-5.33
Volume	8,893